Robert W. Baird Boosts Cooper Companies (NASDAQ:COO) Price Target to $98.00

Cooper Companies (NASDAQ:COO) had its price target upped by equities research analysts at Robert W. Baird from $85.00 to $98.00 in a note issued to investors on Friday, MarketBeat reports. The firm currently has an “outperform” rating on the medical device company’s stock. Robert W. Baird’s price target suggests a potential upside of 20.39% from the stock’s previous close.

COO has been the subject of several other reports. Barclays began coverage on shares of Cooper Companies in a research note on Monday, October 13th. They issued an “overweight” rating and a $85.00 target price for the company. Piper Sandler reiterated an “overweight” rating and set a $94.00 price objective (up previously from $83.00) on shares of Cooper Companies in a report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $100.00 price objective (up previously from $94.00) on shares of Cooper Companies in a research report on Friday. Wells Fargo & Company restated an “equal weight” rating and set a $72.00 target price on shares of Cooper Companies in a research note on Thursday, November 13th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.31.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $81.40 on Friday. The company has a market capitalization of $16.18 billion, a PE ratio of 43.30, a P/E/G ratio of 2.00 and a beta of 1.05. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The company has a 50-day simple moving average of $72.29 and a two-hundred day simple moving average of $71.67. Cooper Companies has a one year low of $61.78 and a one year high of $101.53.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.01%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period last year, the business earned $1.04 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Research analysts expect that Cooper Companies will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has initiated a stock repurchase program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius bought 2,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The shares were purchased at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the transaction, the director directly owned 5,777 shares in the company, valued at approximately $395,089.03. This represents a 52.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.98% of the stock is currently owned by corporate insiders.

Institutional Trading of Cooper Companies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bell Investment Advisors Inc boosted its position in Cooper Companies by 106.3% in the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after purchasing an additional 219 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Cooper Companies in the 1st quarter valued at $33,000. J.Safra Asset Management Corp boosted its holdings in Cooper Companies by 204.8% during the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after buying an additional 340 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new stake in Cooper Companies during the second quarter valued at $36,000. Finally, GKV Capital Management Co. Inc. acquired a new stake in Cooper Companies during the first quarter valued at $40,000. 24.39% of the stock is owned by institutional investors and hedge funds.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.